Last year, i2Vision assisted Palatin in preparing a poster for the ASRS 2021 meeting. Our team provided editorial and graphic assistance. In addition, the team coordinated the communication among authors during the review process (view the case study here). The poster was presented by John Dodd and co-authored by Peter K. Kaiser, Wei H. Yang, Andrew W. Taylor, Tatfong Ng, Marie Makhlina, and Carl Spana. We were glad that the poster received a “Top Ten Poster Winner” award!
See John Dodd’s video receiving the award here.
The poster detailed Palatin’s study on the protective effects of two melanocortin agonists delivered by intravitreal injection in mouse models of diabetic retinopathy and choroidal neovascularization. Monthly IVT treatment with melanocortin agonist PL8331 preserved retinal structure, suppressed VEGF production, and promoted anti-inflammatory activity in a diabetic mouse retina. In a mouse CNV model, melanocortin agonists PL8331 and PL9654 decreased CNV area and leakage, comparable to aflibercept, and decreased fibrosis, trending better than aflibercept.
The melanocortin system plays a key role in promoting the resolution of the inflammatory process. For this reason, targeting it may be protective against ocular disease. Likewise, these findings support the continued development of melanocortin agonists for the treatment of retinal diseases.
Congrats to Palatin on their work. Above all, we are honored to partner with them in such an exciting line of research. We look forward to seeing those promising drugs going into clinical trials!